Evidence map›Paper›PMID 32702198›Full record

ReviewClinical and translational science2021

Pediatric Pharmacokinetics and Dose Predictions: A Report of a Satellite Meeting to the 10th Juvenile Toxicity Symposium.

Bianca D van Groen, Venkatesh Pilla Reddy, Justine Badée, Andrés Olivares-Morales, Trevor N Johnson, Johan Nicolaï, Pieter Annaert, Anne Smits, Saskia N de Wildt, Catherijne A J Knibbe and 1 more

Abstract readReview
In one paragraph

Review in Clinical and translational science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Drug-Induced Liver Injury-Pharmacological Spectrum Among Children.International journal of molecular sciences · 2025
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bianca D van GroenIntensive Care and Department of Pediatric Surgery, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.
Venkatesh Pilla ReddyModelling and Simulation, Early Oncology, Oncology R&D, AstraZeneca, Cambridge, UK.
Justine BadéeCenter for Pharmacometrics & Systems Pharmacology, Department of Pharmaceutics, University of Florida at Lake Nona, Orlando, Florida, USA.
Andrés Olivares-MoralesRoche Pharma and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.
Trevor N JohnsonCertara UK Limited (Simcyp), Sheffield, UK.
Johan NicolaïDevelopment Science, UCB BioPharma SRL, Braine-l'Alleud, Belgium.
Pieter AnnaertDrug Delivery and Disposition, KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium.
Anne SmitsNeonatal Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium.
Saskia N de WildtIntensive Care and Department of Pediatric Surgery, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.
Catherijne A J KnibbeSystems Biomedicine and Pharmacology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands.
Loeckie de ZwartDrug Metabolism and Pharmacokinetics, Janssen R&D, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

On April 24, 2019, a symposium on Pediatric Pharmacokinetics and Dose Predictions was held as a satellite meeting to the 10th Juvenile Toxicity Symposium. This symposium brought together scientists from academia, industry, and clinical research organizations with the aim to update each other on the current knowledge on pediatric drug development. Through more knowledge on specific ontogeny profiles of drug metabolism and transporter proteins, integrated into physiologically-based pharmacokinetic (PBPK) models, we have gained a more integrated understanding of age-related differences in pharmacokinetics (PKs), Relevant examples were presented during the meeting. PBPK may be considered the gold standard for pediatric PK prediction, but still it is important to know that simpler methods, such as allometry, allometry combined with maturation function, functions based on the elimination pathway, or linear models, also perform well, depending on the age range or the mechanisms involved. Knowledge from different methods and information sources should be combined (e.g., microdosing can reveal early read-out of age-related differences in exposure), and such results can be a value to verify models. To further establish best practices for dose setting in pediatrics, more in vitro and in vivo research is needed on aspects such as age-related changes in the exposure-response relationship and the impact of disease on PK. New information coupled with the refining of model-based drug development approaches will allow faster targeting of intended age groups and allow more efficient design of pediatric clinical trials.

Indexed as

Dose-Response Relationship, DrugModels, BiologicalAge FactorsChildChild DevelopmentClinical Trials as TopicCongresses as TopicCytochrome P-450 Enzyme SystemGene Expression Regulation, DevelopmentalGlucuronosyltransferaseHumansMetabolic Clearance RateResearch DesignTissue DistributionCytochrome P-450 Enzyme SystemGlucuronosyltransferase

Identifiers

PMID32702198
PMCPMC7877839

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.